Companies › Serina Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SER-252 (PEOZ-apomorphine) Dopamine receptor agonist (D1-like and D2-like dopamine receptors) | DRD1, DRD2, DRD3, DRD4, DRD5 | Phase 1 | PARKINSON DISEASE (Disorder) | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07422675 | SER-252 (PEOZ-apomorphine) | Phase 1 | PARKINSON DISEASE (Disorder) | Neurology | Jan 2027 |
Cash of $23m on 2026-06-30; operating cash outflow about $23m a year; runway about 12 months at that burn, to Jul 2027
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.